Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) confirmed by imaging scans, tissue sample, or cell testing
• People whose liver cancer is classified as an advanced stage (BCLC Stage C), meaning the cancer has spread outside the liver and/or has grown into major blood vessels
• People who have not previously received any systemic (whole-body) treatment for their liver cancer, such as chemotherapy, targeted therapy, or immunotherapy
• People whose treatment included only commercially available (approved and marketed) checkpoint inhibitor drugs (PD-1/PD-L1 inhibitors) and anti-angiogenic drugs, though these do not need to be specifically approved for liver cancer
• People who received a procedure called TACE (a treatment delivered directly to the liver's blood vessels) either after starting the above drug combination, or up to 3 months before starting it
• People who received at least one full cycle of the combination drug therapy (PD-1/PD-L1 inhibitor plus anti-angiogenic drug) after the TACE procedure
• People who have measurable liver tumours that can be tracked on repeated imaging

Who may not be able to join:

• People whose liver cancer is a specific subtype, including cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, or mixed hepatocellular/cholangiocarcinoma, as confirmed by tissue or pathology testing
• People whose treatment history does not fit the required timing described in the inclusion criteria
• People with severely reduced liver function (Child-Pugh Class C), a physical performance status score above 2, or severe brain complications related to liver disease (hepatic encephalopathy)

Important: Always verify eligibility with the trial site directly before applying.